The exact molecular functions of Polo-like kinase 1 (PLK1) in mitotic prophase are not fully understood. This study shows ...
Hosted on MSN1mon
ProPhase Labs Stock Hits 52-Week Low at $0.56 Amid Market StrugglesProPhase Labs is currently seeking ways to meet ... The esophageal cancer test could be commercialized by late 2025 or early 2026, targeting a market worth $7 to $14 billion.
ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced that Ted Karkus, CEO, will be presenting at this ...
ProPhase Labs, Inc. announced that CEO Ted Karkus ... This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer ...
ProPhase Labs Accelerates Potential Liquidity ... with material cash flows potentially commencing as early as mid-2025. Concurrently, the company is exploring strategic alternatives that include ...
ProPhase Labs (NASDAQ:PRPH) stock rose +12% Tuesday premarket as it named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered ...
GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback